XXXII Porto Cancer Meeting
Bridging Research and Policy in Hereditary Cancer
a Joint Conference with the Horizon Europe Preventable project

22nd - 24th April 2026 | i3S and SuperBock Arena – Pavilhão Rosa Mota, Porto, Portugal

The Porto Cancer Meeting

It is our great pleasure to welcome you to the XXXII Edition of the Porto Cancer Meeting. This renowned international meeting has been organized since 1990 by the Institute of Molecular Pathology and Immunology of the University of Porto, well-known as Ipatimup. 
The Porto Cancer Meeting is now a flagship meeting of the Institute for Research and Innovation in Health – i3S – the largest health research institute in Portugal. This scientific event will be part of the celebrations of the 10th Anniversary of i3S, highlighting a decade of scientific excellence, collaboration, and impact.

The XXXII Porto Cancer Meeting Theme in 2026

This Porto Cancer Meeting will be dedicated to heritable cancers, lying at the interface between basic research and real-world applications in the form of health policies.
Hereditary cancers are less common than sporadic cancers, tend to develop at a younger age, and often impact multiple family members, posing significant social, clinical, and economic challenges. They require specialized and multidisciplinary care, because prevention and treatment can be complex. However, as these cancers are caused by inherited genetic changes, genetic testing can identify the underlying risk. This enables proactive monitoring, early diagnosis, and application of preventive and more personalized measures, as well as targeted treatments.

To discuss challenges and opportunities in the field of inherited cancers, the XXXII Porto Cancer Meeting scientific program in 2026 will revolve around the genetics and biology of these cancers, their distinctive clinical pathways of care, social intricacies, and cost of healthcare for patients, hospitals and the society as a whole. This year, the Porto Cancer Meeting will embrace the final conference of the EU-funded project Preventable [www.preventable.eu], which has established pathways of care from several rare tumour risk syndromes, their respective costs and cost-effectiveness, as well as guidelines to improve communication between the various stakeholders moving around this ecosystem. 

A special flavour brought in by the Preventable project into the Porto Cancer Meeting, is the presence of patients and families suffering from rare tumour risk syndromes, from many European countries, which have actively participated in the project, further extending the real impact of this event. 

The meeting is expected to bring together patients, Healthcare Professionals, Scientists working in Basic and Clinical aspects of heritable cancers, Health Economics and Social Sciences, as well as Policy Officers and Health Managers from the European Health Management Association – EHMA, Decision-makers from Europe, and beyond. It will also mark the launch of the ‘Preventable Learning Hub’, a novel online resource of educational contents, designed specifically for at-risk individuals and their families, but also for healthcare providers and policymakers, integrating expert perspectives, real-life testimonies, visual infographics and guidelines, to promote knowledge, better decision-making, and evidence-based practices.

This joint conference between the Porto Cancer Meeting and the Preventable project will start at the i3S, in the afternoon of the 22nd of April 2026, with a welcome to participants by the Organizers and the i3S, a keynote lecture and a Porto d’Honra, as part of the celebration of the 10th Anniversary of the i3S.

The conference will continue on the 23rd of April, at the Super Bock Arena Conference Centre, in the heart of Porto, for another two days, and till the end of the 24th of April.

The program is designed to attract a diverse range of participants to foster multidisciplinary discussions that advance the field and support sustainable, resilient health systems for individuals at high risk of cancer. The joint Conference serves as a platform for renowned researchers, professionals, and patients to discuss recent advances in hereditary cancer research, disease management, healthcare costs, and prevention and treatment strategies. 

Centred around the theme “Bridging Research and Policy in Hereditary Cancer Prevention and Care,” the XXXII Porto Cancer Meeting emphasizes the urgent need for innovative, scalable solutions to ensure accessible, equitable, and sustainable care for patients with tumour risk syndromes across Europe.

The long-term goal is to move beyond simply managing these rare patients, to actively shape disease prevention, early diagnosis, and healthcare resilience at all levels, supported by forefront scientific discoveries, that allows moving from ‘one solution fits all’ to ‘patient-centred care settings’.

The Organizing Committee looks forward to welcome all participants and patients to the historic and vibrant city of Porto, a World Heritage Site by UNESCO.

Carla Oliveira 
Conference Chair, on behalf of the Organizing Committee

Poster >> 
 

Local Organizing Committee
Carla Oliveira, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal
Sara Pereira, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal
Liliana Sousa, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal
Silvana Lobo, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal
Daniel Ferreira (i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal)
Nuno Marcos, Ipatimup - Institute of Molecular Pathology and Immunology of the University of Porto, Portugal
Ana Gomes, Ipatimup - Institute of Molecular Pathology and Immunology of the University of Porto, Portugal
Igor Lopes, Sociedade Portuguesa de Inovação, Portugal
Laurène Mathey, European Health Management Association, Belgium
Bárbara Peleteiro, Unidade Local de Saúde de São João (ULSSJ), Portugal

Scientific Committee
Joan Brunet, Catalan Institute of Oncology, Spain
Carla Oliveira, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal
Céu Mateus, Lancaster University, UK
Marta Marques, Escola Nacional de Saúde Pública; Universidade Nova de Lisboa, Portugal
Alexis Strader, European Health Managment Association, Belgium
Judith Balmaña, Vall d’Hebron Institute of Oncology, Spain
Ricardo Amorim, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal
Tamara Milagre, EVITA Patients Association, Portugal
Nicoline Hoogerbrugge, European Reference Network GENTURIS, Belgium
Susana Sampaio Oliveira, Faculdade Economia da Universidade do Porto, Portugal
Joana Paredes, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal
Sandra Tavares, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal

The call for abstracts is open and the deadline for abstract submission is the January 16th 2026 (notification of acceptance will be sent until February 16th 2026).

Abstract scientific review will be performed by members of the scientific committee, that are not authors in abstracts submitted to the meeting.

Candidates can select their preference for an oral or poster presentation.
Abstracts must be submitted by completing the online submission form.

Abstracts guidelines/ layout »

Abstract submission form »

Registration fee

Includes the welcome coffee and Porto D'Honra on April 22^nd; coffee breaks and lunches on April 23^rd-24^th. 
Participation in the meeting dinner requires an additional payment of €55.
 

* Limited to 50 participants.

** Students should enclose a letter confirming their status signed by their supervisors or other documents that prove their status.

Registration form »

More information:
Events Management Unit | Rua Alfredo Allen 208 | 4200-135 Porto, Portugal
Email: events@i3s.up.pt | Tel: +351 226 074 900